The 61 references in paper S. Avdeev N., С. Авдеев Н. (2014) “ТИОТРОПИЯ БРОМИД ДЛЯ ТЕРАПИИ ХРОНИЧЕСКОЙ ОБСТРУКТИВНОЙ БОЛЕЗНИ ЛЕГКИХ: СЛАГАЕМЫЕ УСПЕХА // TIOTROPIUM BROMIDE IN THERAPY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A RECIPE FOR SUCCESS” / spz:neicon:pulmonology:y:2011:i:1:p:100-106

1
Global Initiative for Chronic Obstructive Lung Diseas (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. The 2009 report is available on www.goldcopd.com
(check this in PDF content)
2
Buist A.S., McBurnie M.A., Vollmer W.M. et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741–750.
(check this in PDF content)
3
Чучалин А.Г., Овчаренко С.И., Лещенко И.В., Белев% ский А.С. Определение, классификация и диагностика ХОБЛ. В кн.: Чучалин А.Г. (ред.). Клинические рекомендации. Хроническая обструктивная болезнь легких. М.: Атмосфера, 2007. 8–22.
(check this in PDF content)
4
Celli B.R., MacNee W.,ATS / ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932–946.
(check this in PDF content)
5
Panning C.A., DeBisschop M.Tiotropium: an inhaled, longacting anticholinergic drug for chronic obstructive pulmonary disease. Pharmacotherapy 2003; 23: 183–189.
(check this in PDF content)
6
Tashkin D.P. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. Curr. Opin. Pulm. Med. 2010; 16: 97–105.
(check this in PDF content)
7
Donohue J.F., van Noord J.A., Bateman E.D. et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47–55.
(check this in PDF content)
8
Celli B., Wallack R.Z., Wang S. et al.Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743–1748.
(check this in PDF content)
9
Cazzola M., Matera M.G.Emerging inhaled bronchodilators: an update. Eur. Respir. J. 2009; 34: 757–769.
(check this in PDF content)
10
Bauwens O., Ninane V., Van de Maele B. et al. 24-hour bronchodilator efficacy of single doses indacaterol in subjects Обзоры with COPD: comparison with placebo and formoterol. Curr. Med. Res. Opin. 2009; 25: 463–470.
(check this in PDF content)
11
Beier J., Beeh K.M., Brookman L. et al. Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm. Pharmacol. Ther. 2009; 22 (6): 492–496.
(check this in PDF content)
12
Fogarty C., Worth H., Hebert J. et al. Sustained 24-h bronchodilation with indacaterol once-daily in COPD: a 26-week efficacy and safety study. Am. J. Respir. Crit. Care Med. 2009; 179: A4547.
(check this in PDF content)
13
Magnussen H., Paggiaro P., Jack D. et al.Bronchodilatador treatment with indacaterol once-daily vs formoterol twicedaily in COPD: a 52-week study. Am. J. Respir. Crit. Care Med. 2009; 179: A6184.
(check this in PDF content)
14
Nonikov V., Verkindre C., Jack D. et al.Indacaterol oncedaily reduces days of poor control in COPD over 52 weeks of treatment. Am. J. Respir. Crit. Care Med. 2009; 179: A6190.
(check this in PDF content)
15
Magnussen H., Paggiaro P., Jack D. et al.Indacaterol oncedaily improves health-related quality of life in COPD patients: a 52-week study versus placebo and formoterol. Eur. Respir. J. 2009; 53s: P2019.
(check this in PDF content)
16
Buhl R., Pieters W., Jack D. et al.Indacaterol once-daily improves dyspnoea and BODE index in COPD patients: a 52-week study versus twice-daily formoterol. Eur. Respir. J. 2009; 53s: P2026.
(check this in PDF content)
17
Buhl R., Pieters W., Jack D. et al. Indacaterol once-daily reduces COPD exacerbations over 52 weeks of treatment. Am. J. Respir. Crit. Care Med. 2009; 179: A6185.
(check this in PDF content)
18
Worth H., Kleerup E., Iqbal A. et al.Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study. Eur. Respir. J. 2009; 53s: P2030.
(check this in PDF content)
19
Chung F., Kornmann O., Jack D. et al.Safety and tolerability of indacaterol over 52 weeks of treatment in COPD. Eur. Respir. J. 2009; 53s: E4359.
(check this in PDF content)
20
Fletcher C.M., Elmes P.C., Wood C.H.The significance of respiratory symptoms and the diagnosis of chromic bronchitis in a working population. Br. Med. J. 1959; 1: 257–266.
(check this in PDF content)
21
Kohansal R., Martinez%Camblor P., Agusti A. et al.The natural history of chronic airflow obstruction revisited: an analysis of the framingham offspring cohort. Am. J. Respir. Crit. Care Med. 2009; 180: 3–10.
(check this in PDF content)
22
Decramer M., Celli B., Tashkin D.P. et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the Uplift trial. COPD 2004; 1: 303–312.
(check this in PDF content)
23
Scanlon P.D., Connett J.E., Waller L.A. et al.Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease: the Lung Health Study. Am. J. Respir. Crit. Care Med. 2000; 161: 381–390.
(check this in PDF content)
24
Anthonisen N.R., Skeans M.A.,Wise R.A. et al.The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 2005; 142: 233–239.
(check this in PDF content)
25
Tashkin D.P., Celli B., Senn S. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543–1554.
(check this in PDF content)
26
Vincken W., van Noord J.A., Greefhorst A.P.M. et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. 2002; 19: 209–216.
(check this in PDF content)
27
Anzueto A., Tashkin D., Menjoge S., Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm. Pharmacol. Ther. 2005; 18: 75–81.
(check this in PDF content)
28
Pauwels R.A., Lofdahl C.G., Laitinen L.A. et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N. Engl. J. Med. 1999; 340: 1948–1953.
(check this in PDF content)
29
Vestbo J., Sorensen T., Lange P. et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819–1823.
(check this in PDF content)
30
The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N. Engl. J. Med. 2000; 343: 1902–1909.
(check this in PDF content)
31
Burge P.S., Calverley P.M.A., Jones P.W. et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. 2000;
(check this in PDF content)
32
1297–1303. 32.Decramer M., Rutten%van Molken M., Dekhuijzen P.N. et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebocontrolled trial. Lancet 2005; 365: 1552–1560.
(check this in PDF content)
33
Calverley P., Pauwels R., Vestbo J. et al. Combined salmeterol and fluticasone in the treatment of COPD: a randomised controlled trial. Lancet 2003; 361 (9356): 449–456.
(check this in PDF content)
34
Decramer M., Celli B., Kesten S. et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171–1178.
(check this in PDF content)
35
Troosters T., Celli B., Lystig T. et al. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur. Respir. J. 2010; 36: 65–73.
(check this in PDF content)
36
Morice A.H., Celli B., Kesten S. et al. COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT). Respir. Med. 2010; 104: 1659–1667.
(check this in PDF content)
37
Murray C.J.L., Lopez A.D.Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269–1276.
(check this in PDF content)
38
Mannino D.M., Homa D.M., Akinbami L.J. et al.Chronic obstructive pulmonary disease surveillance – United States, 1971–2000. Morbid. Mortal. Wkly Rep. Surveill. Summ. 2002; 51: 1–16.
(check this in PDF content)
39
World Health Organization. Global initiative for chronic obstructive lung disease. Geneva (Switzerland): World Health Organization; 2002.
(check this in PDF content)
40
Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1: 681–686.
(check this in PDF content)
41
Nocturnal Oxygen Therapy Trial Group: Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann. Intern. Med. 1980; 93: 391–398.
(check this in PDF content)
42
Anthonisen N.R., Skeans M.A.,Wise R.A. et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 2005; 142: 233–239.
(check this in PDF content)
43
National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N. Engl. J. Med. 2003; 348: 2059–2073.
(check this in PDF content)
44
Lightowler J.V., Wedzicha J.A., Elliott M.W., Ram F.S. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. Br. Med. J. 2003; 326: 185–189. Авдеев С.Н. Тиотропия бромид для терапии ХОБЛ: слагаемые успеха
(check this in PDF content)
45
Salpeter S.R., Buckley N.S., Salpeter E.E.Meta-analysis: Anticholinergics, but not β-agonists, reduce severe exacerbations and respiratory mortality in COPD. J. Gen. Intern. Med. 2006; 21: 1011–1019.
(check this in PDF content)
46
Luise C., Lanes S.F., Jacobsen J. et al.Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark. Eur. J. Epidemiol. 2007; 22: 267–272.
(check this in PDF content)
47
Hansell A.L., Walk J.A., Soriano J.B. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur. Respir. J. 2003; 22: 809–814.
(check this in PDF content)
48
Camilli A.E., Robbins D.R., Lebowitz M.D. Death certificate reporting of confirmed airways obstructive disease. Am. J. Epidemiol. 1991; 133: 795–800.
(check this in PDF content)
49
Engstrom G., Wollmer P., Hedblad B. et al. Occurrence and prognostic significance of ventricular arrhythmia is related to pulmonary function: a study from "men born in 1914", Malmo, Sweden. Circulation 2001; 103: 3086–3091.
(check this in PDF content)
50
Huiart L., Ernst P., Suissa S.Cardiovascular morbidity and mortality in COPD. Chest 2005; 128: 26400–2646.
(check this in PDF content)
51
Viegas C.A., Ferrer A., Montserrat J.M. Ventilation-perfusion response after fenoterol in hypoxemic patients with stable COPD. Chest 1996; 110: 71–77.
(check this in PDF content)
52
Singh S., Loke Y.K., Furberg C.D. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. A systematic review and meta-analysis. J.A.M.A. 2008; 300: 1439–1450.
(check this in PDF content)
53
Celli B., Decramer M., Leimer I. et al.Cardiovascular safety of tiotropium in patients with COPD. Chest 2010; 137; 20–30.
(check this in PDF content)
54
Reilly J.J. COPD and declining FEV1– time to divide and conquer? N. Engl. J. Med. 2008; 359: 1616–1618.
(check this in PDF content)
55
Burrows B., Fletcher C.M., Heard B.E. et al. The emphysematous and bronchial types of chronic airways obstruction. A clinicopathological study of patients in London and Chicago. Lancet 1966; 87: 830–835.
(check this in PDF content)
56
Garcia%Aymerich J., Agusti А., Barberа J.A. et al.Phenotypic heterogeneity of chronic obstructive pulmonary disease. Arch. Bronconeumol. 2009; 45: 133–142.
(check this in PDF content)
57
Han M.K., Agusti A., Calverley P.M. et al.COPD phenotypes: The future of COPD. Am. J. Respir. Crit. Care Med. 2010; 182: 598–604.
(check this in PDF content)
58
Lee J.%H., Lee Y.K., Kim E.%K. et al. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respir. Med. 2010; 104: 542–549.
(check this in PDF content)
59
Gelb A.F., Taylor C.F., Cassino C. et al. Tiotropium induced bronchodilation and protection from dynamic hyperinflation is independent of extent of emphysema in COPD. Pulm. Pharmacol. Ther. 2009; 22: 237–242.
(check this in PDF content)
60
Tashkin D.P., Celli B., Kesten S. et al. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur. Respir. J. 2010; 35: 287–294.
(check this in PDF content)
61
Tashkin D.P., Celli B., Kesten S. et al. Effect of tiotropium in men and women with COPD: Results of the 4-year UPLIFT trial. Respir. Med. 2010; 104: 1495–1504. Информация об авторе Авдеев Сергей Николаевич – д. м. н., проф., руководитель клинического
(check this in PDF content)